Nordicus Partners Corp (NORD) stock: key figures, P/E, revenue and dividend
Industrials · United States · ISIN USG6583A1028
Nordicus Partners Corp financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 5,000.00 USD | – |
| Operating income | -2.92 m USD | -4.37 m USD |
| EBIT | -2.92 m USD | -4.05 m USD |
| Net income | -2.90 m USD | -4.00 m USD |
| Diluted EPS – continuing operations | -0.32 USD | -0.22 USD |
Full history since 2010, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Nordicus Partners Corp
Nordicus Partners Corporation, a biotech company specializing in developing breakthrough therapeutics for diseases with unmet medical needs in the United States. It develops medicines supporting oral health. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California.
More stocks
- Spero Therapeutics, Inc. (SPRO)
- Santierul Naval Orsova SA (SNO.RO)
- Nordwest Handel AG (NWX.F)
- Young Shine Electric Co., Ltd. (2249.TWO)
- Advanced Lithium Electrochemistry Cayman Co Ltd (5227.TWO)
- DIVA Laboratories Ltd (4153.TWO)
- Trans-Sun Materials Technology Company Limited (6967.TWO)
- THN Corporation (019180.KS)
- Taiwan Auto-Design Co. (6791.TWO)
- West Shore Bank Corp (WSSH)
- TY Holdings Co Ltd (363280.KS)
- Jingbo Technology, Inc. (SVMB)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.